NCT00127127 2022-09-13
MK-0683-029
Merck Sharp & Dohme LLC
Phase 1 Completed
Clinical Trials
3 trialsNCT01266057 2021-03-04
Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00750178 2017-04-07
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)
Merck Sharp & Dohme LLC
Phase 1 Completed